Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated
